Current transfusion medicine entirely relies on donated
blood. Megakaryon will change the transfusion practices by supplying
safe and cost-saving platelets produced in vitro. Mass production in
Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder.
